PROTEASOMINHIBITOREN

European patent · EP2212334 · In force

Register entry

Publication number
EP2212334
Application number
EP07839608
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Oct 16, 2007
Published
Aug 4, 2010
Granted
Aug 15, 2012
Protection ends at the latest
Oct 15, 2027
Next annual fee due
Oct 31, 2026
IPC classes
C07F 5/02 (2006.01)
C07K 5/04 (2006.01)
C07K 5/06 (2006.01)
A61K 38/06 (2006.01)
A61K 38/04 (2006.01)
PCT application
PCT/US2007/022079 16.10.2007
PCT publication
WO2009/051581 23.04.2009
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Nov 1, 2025

    Change

    Published in Swissreg on 01.11.2025

  2. Nov 1, 2024

    Change

    Published in Swissreg on 01.11.2024

  3. Nov 1, 2023

    Change

    Published in Swissreg on 01.11.2023

  4. Nov 1, 2022

    Change

    Published in Swissreg on 01.11.2022

  5. Aug 16, 2012

    Agent entered

    Representative
    Kirker & Cie S.A., 122, rue de Genève, Case postale 90, 1226 Geneve-Thônex

    Published in Swissreg on 16.08.2012

  6. Aug 15, 2012

    Granted

    Published in Swissreg on 15.08.2012

Parties

Holder

Millennium Pharmaceuticals, Inc.

40 Landsdowne Street, Cambridge, MA 02139, US

Agent

Kirker & Cie SA

Kirker & Cie S.A.

122, rue de Genève Case postale 90, 1226 Geneve-Thônex

Inventor

OLHAVA, Edward, J.

Newton MA 02460, US

DANCA, Miheala, D.

Mendham NJ 07945, US

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.